利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

63 条记录 (耗时 0.029 秒)

    EYE DROPS
    4.
    发明申请
    EYE DROPS 有权
    眼药水

    公开(公告)号：US20120165273A1

    公开(公告)日：2012-06-28

    申请号：US13394194

    申请日：2010-09-24

    申请人： Takahiro Nakamura ,  Yuichiro Nakada ,  Takashi Nagano ,  Masatsugu Nakamura

    发明人： Takahiro Nakamura ,  Yuichiro Nakada ,  Takashi Nagano ,  Masatsugu Nakamura

    IPC分类号： A61K38/07 ,  A61P27/02

    CPC分类号： A61K38/07 ,  A61K9/0048 ,  C07K5/1013 ,  C07K5/1016 ,  A61K2300/00

    摘要： An eyedrop containing a peptide having an amino acid sequence represented by Ser-Ser-Ser-Arg (“SSSR”), or a pharmacologically acceptable salt thereof; and a peptide having an amino acid sequence represented by Phe-Gly-Leu-Met-NH2 (“FGLM”), or a pharmacologically acceptable salt thereof. The concentration ratio between SSSR or a pharmacologically acceptable salt thereof and FGLM or a pharmacologically acceptable salt thereof is between 1/15 and 1/50. The concentration of SSSR or a pharmacologically acceptable salt thereof is between 0.001% and 0.3% (w/v) and the concentration of FGLM or a pharmacologically acceptable salt thereof is between 0.015% and 1.5% (w/V). The pH of the eye drop is maintained between 2.5 and 6.5.

    摘要翻译： 含有具有由Ser-Ser-Ser-Arg（“SSSR”）表示的氨基酸序列的肽或其药理学上可接受的盐的滴眼剂; 和具有由Phe-Gly-Leu-Met-NH 2（“FGLM”）表示的氨基酸序列的肽或其药理学上可接受的盐。 SSSR或其药理学上可接受的盐与FGLM或其药理学上可接受的盐之间的浓度比为1/15至1/50。 SSSR或其药理学上可接受的盐的浓度为0.001％至0.3％（w / v），并且FGLM或其药理学上可接受的盐的浓度为0.015％至1.5％（w / V）。 滴眼液的pH值保持在2.5至6.5之间。

    Eye drops
    5.
    发明授权
    Eye drops 有权
    眼药水

    公开(公告)号：US08865654B2

    公开(公告)日：2014-10-21

    申请号：US13394194

    申请日：2010-09-24

    申请人： Takahiro Nakamura ,  Yuichiro Nakada ,  Takashi Nagano ,  Masatsugu Nakamura

    发明人： Takahiro Nakamura ,  Yuichiro Nakada ,  Takashi Nagano ,  Masatsugu Nakamura

    IPC分类号： A61K38/00 ,  A61P9/10 ,  A61P27/02 ,  A61K38/07 ,  A61K9/00 ,  C07K5/107 ,  C07K5/103

    CPC分类号： A61K38/07 ,  A61K9/0048 ,  C07K5/1013 ,  C07K5/1016 ,  A61K2300/00

    摘要： An eyedrop containing a peptide having an amino acid sequence represented by Ser-Ser-Ser-Arg (“SSSR”), or a pharmacologically acceptable salt thereof; and a peptide having an amino acid sequence represented by Phe-Gly-Leu-Met-NH2 (“FGLM”), or a pharmacologically acceptable salt thereof. The concentration ratio between SSSR or a pharmacologically acceptable salt thereof and FGLM or a pharmacologically acceptable salt thereof is between 1/15 and 1/50. The concentration of SSSR or a pharmacologically acceptable salt thereof is between 0.001% and 0.3% (w/v) and the concentration of FGLM or a pharmacologically acceptable salt thereof is between 0.015% and 1.5% (w/V). The pH of the eye drop is maintained between 2.5 and 6.5.

    摘要翻译： 含有具有由Ser-Ser-Ser-Arg（“SSSR”）表示的氨基酸序列的肽或其药理学上可接受的盐的滴眼剂; 和具有由Phe-Gly-Leu-Met-NH 2（“FGLM”）表示的氨基酸序列的肽或其药理学上可接受的盐。 SSSR或其药理学上可接受的盐与FGLM或其药理学上可接受的盐之间的浓度比为1/15至1/50。 SSSR或其药理学上可接受的盐的浓度为0.001％至0.3％（w / v），并且FGLM或其药理学上可接受的盐的浓度为0.015％至1.5％（w / V）。 滴眼液的pH值保持在2.5至6.5之间。

    THERAPEUTIC AGENT FOR GASTROINTESTINAL DISEASE
    6.
    发明申请
    THERAPEUTIC AGENT FOR GASTROINTESTINAL DISEASE 审中-公开
    胃肠病治疗药物

    公开(公告)号：US20120225817A1

    公开(公告)日：2012-09-06

    申请号：US13505627

    申请日：2010-11-10

    申请人： Teruo Nishida ,  Makoto Inui ,  Kenji Matsuura ,  Masatsugu Nakamura ,  Takashi Nagano

    发明人： Teruo Nishida ,  Makoto Inui ,  Kenji Matsuura ,  Masatsugu Nakamura ,  Takashi Nagano

    IPC分类号： A61K38/07 ,  A61P29/00 ,  A61P1/00 ,  C07K5/103 ,  A61P1/04

    CPC分类号： A61K38/07 ,  C07K5/1013 ,  C07K5/1016

    摘要： The present invention provides a therapeutic agent and a prophylactic agent for a gastrointestinal disease. A peptide having an amino acid sequence represented by Ser-Ser-Ser-Arg or a pharmaceutically acceptable salt thereof promotes wound healing in a gastrointestinal mucosal tissue, and is therefore useful as a therapeutic agent or a prophylactic agent for a gastrointestinal disease. Further, when (a) a peptide having an amino acid sequence represented by Ser-Ser-Ser-Arg or a pharmaceutically acceptable salt thereof and (b) a peptide having an amino acid sequence represented by Phe-Gly-Leu-Met-NH2 or a pharmaceutically acceptable salt thereof are administered in combination, these medicaments act synergistically and can significantly promote wound healing in a gastrointestinal mucosal tissue.

    摘要翻译： 本发明提供了治疗剂和胃肠道疾病的预防剂。 具有由Ser-Ser-Ser-Arg表示的氨基酸序列的肽或其药学上可接受的盐在胃肠粘膜组织中促进伤口愈合，因此可用作胃肠道疾病的治疗剂或预防剂。 此外，（a）具有Ser-Ser-Ser-Arg表示的氨基酸序列的肽或其药学上可接受的盐和（b）具有由Phe-Gly-Leu-Met-NH 2表示的氨基酸序列的肽 或其药学上可接受的盐组合施用，这些药物协同作用并且可显着促进胃肠粘膜组织中的伤口愈合。

    OPHTHALMIC SOLUTION FOR TREATING OCULAR INFECTION COMPRISING LEVOFLOXACIN OR SALT THEREOF OR SOLVATE OF THE SAME, METHOD FOR TREATING OCULAR INFECTION, LEVOFLOXACIN OR SALT THEREOF OR SOLVATE OF THE SAME, AND USE THEREOF
    7.
    发明申请
    OPHTHALMIC SOLUTION FOR TREATING OCULAR INFECTION COMPRISING LEVOFLOXACIN OR SALT THEREOF OR SOLVATE OF THE SAME, METHOD FOR TREATING OCULAR INFECTION, LEVOFLOXACIN OR SALT THEREOF OR SOLVATE OF THE SAME, AND USE THEREOF 审中-公开
    用于治疗包含左炔诺孕酮或其盐或其溶解物的卵巢感染的眼科解决方案，用于治疗卵巢感染的方法，利福昔康或其盐或其溶解物的方法及其用途

    公开(公告)号：US20120316158A1

    公开(公告)日：2012-12-13

    申请号：US13580931

    申请日：2010-12-16

    申请人： Takashi Nagano ,  Koji Sakanaka ,  Masatsugu Nakamura ,  Kouichi Kawazu ,  Hajime Ibuki ,  Kayoko Sakamoto

    发明人： Takashi Nagano ,  Koji Sakanaka ,  Masatsugu Nakamura ,  Kouichi Kawazu ,  Hajime Ibuki ,  Kayoko Sakamoto

    IPC分类号： A61K31/5383 ,  A61P31/04 ,  A61P29/00 ,  A61P31/00 ,  A61P27/02

    CPC分类号： A61K31/5383 ,  A61K9/0048

    摘要： Instillation of a 1.5% (w/v) levofloxacin ophthalmic solution three times a day, which is the dosage or dose regimen of the present invention, has features to cure bacterial conjunctivitis in a shorter time than instillation of a 0.5% (w/v) ophthalmic solution three times a day, which is the conventional dosage or dose regimen, and not to increase the rate of occurrence of side effects. Curing the ocular infection in a short time leads to shortening of the duration of exposure of the ocular-infection-causing bacterium to levofloxacin. Therefore, the levofloxacin ophthalmic solution in the dosage or dose regimen of the present invention is eventually expected to suppress emergence of the resistant bacterium resulting from the long-term use of the levofloxacin ophthalmic solution in the conventional dosage or dose regimen. In addition, it is confirmed that the levofloxacin ophthalmic solution in the dosage or dose regimen of the present invention directly inhibits the ocular-infection-causing bacterium such as Staphylococcus aureus from becoming resistant to levofloxacin, which results from the short-term use of the levofloxacin ophthalmic solution in the conventional dosage or dose regimen.

    摘要翻译： 每天三次（即本发明的剂量或剂量方案）滴注1.5％（w / v）左氧氟沙星眼用溶液具有在比滴注0.5％（w / v）的时间更短的时间内治愈细菌性结膜炎的特征 ）眼用溶液每天三次，这是常规剂量或剂量方案，而不是增加副作用的发生率。 在短时间内治疗眼部感染导致引起眼睛感染的细菌暴露于左氧氟沙星的持续时间缩短。 因此，本发明的剂量或剂量方案中的左氧氟沙星眼用溶液最终预期会抑制由常规剂量或剂量方案中长期使用左氧氟沙星眼用溶液引起的耐药性细菌的出现。 此外，证实本发明的剂量或剂量方案中的左氧氟沙星眼用溶液直接抑制例如金黄色葡萄球菌引起的眼睛感染的细菌变得对左氧氟沙星具有抗性，这是由于短期使用 左氧氟沙星眼科溶液在常规剂量或剂量方案中。

    Polysaccharide-containing composition and tear film stabilizing ophthalmic solution
    8.
    发明申请
    Polysaccharide-containing composition and tear film stabilizing ophthalmic solution 审中-公开
    含多糖组合物和眼膜稳定眼科溶液

    公开(公告)号：US20070077278A1

    公开(公告)日：2007-04-05

    申请号：US10577970

    申请日：2004-11-10

    申请人： Yukiko Sugihara ,  Akio Kimura ,  Masatsugu Nakamura ,  Kazuhiro Tanashashi ,  Miho Araki ,  Takashi Taniguchi

    发明人： Yukiko Sugihara ,  Akio Kimura ,  Masatsugu Nakamura ,  Kazuhiro Tanashashi ,  Miho Araki ,  Takashi Taniguchi

    IPC分类号： A61K31/729

    CPC分类号： A61K9/0048 ,  A61K47/36

    摘要： An object of the present invention is to provide a composition which is excellent in safety and capable of dispersing uniformly on the mucous tissue when topically administered to mammals, and an ophthalmic solution comprising the composition and capable of stabilizing the tear film and keeping the tear film on the eyeball surface smooth. In a composition comprising a polysaccharide, particularly agar, and water as essential components, an ophthalmic solution comprising the agar-containing composition of which an amount of precipitated agar after performing centrifugal separation at with 40,000 ×g is less than 65 wt % of a total agar content has an excellent tear film stabilizing effect which was proved by a test on changes of corneal surface irregularity. Therefore, the agar-containing ophthalmic solution of the present invention has the effect of stabilizing the tear film on the eyeball surface over a prolonged period of time and is usable as an artificial tear fluid.

    摘要翻译： 本发明的目的在于提供一种组合物，其安全性优异，能够均匀地分散在哺乳动物局部施用的粘膜组织上时，还含有该组合物的眼用溶液，能够使泪液膜稳定并保持泪液膜 在眼球表面光滑。 在包含多糖，特别是琼脂和水作为必要组分的组合物中，包含含有琼脂的组合物的眼用溶液的用量为40,000×g离心分离后的沉淀琼脂的量小于总琼脂的65重量％ 内容物具有优异的泪膜稳定作用，通过对角膜表面不规则变化的测试证明。 因此，本发明的含有琼脂的眼用溶液具有使眼球表面上的泪膜长时间稳定的效果，可用作人工泪液。

    Image forming apparatus
    9.
    发明申请
    Image forming apparatus 失效
    图像形成装置

    公开(公告)号：US20070058199A1

    公开(公告)日：2007-03-15

    申请号：US11497674

    申请日：2006-08-01

    申请人： Hiroshi Kawano ,  Masatsugu Nakamura ,  Shinji Imagawa ,  Takashi Kitagawa ,  Masaaki Ohtsuki

    发明人： Hiroshi Kawano ,  Masatsugu Nakamura ,  Shinji Imagawa ,  Takashi Kitagawa ,  Masaaki Ohtsuki

    IPC分类号： H04N1/40

    CPC分类号： G03G15/556 ,  G03G15/0856 ,  G03G15/5041 ,  G03G15/5079 ,  G03G15/553

    摘要： A small domain generation section generates a plurality of small domains in a multi-valued image transmitted from an intermediate tone correction section. Each domain is constituted of a plurality of pixels. Counting means counts a signal input value of each pixel. Weighting calculation means corrects each signal input value of the “pixels subjection to toner quantity equivalent value calculation” with reference to the signal input value of the small domain, and reads out a weighting coefficient from the weighting coefficient table based on the modified signal input value. The weighting calculation means multiplies the signal input value by the coefficient so as to convert the signal input value into a toner quantity equivalent value. Accumulating means calculates toner quantity equivalent values for all of the pixels of the multi-valued image. A total toner quantity equivalent value calculation section determines a total toner quantity equivalent value by accumulating all of the toner quantity equivalent values which are individually calculated each time an image is processed. When the total toner quantity equivalent value reaches a predetermined value, conditions for process control is set. On this account, the present invention achieves an image forming apparatus capable of accurate estimation of toner consumption quantity.

    摘要翻译： 小域生成部在从中间色调校正部发送的多值图像中生成多个小域。 每个域由多个像素组成。 计数装置计算每个像素的信号输入值。 加权计算装置参考小域的信号输入值来校正“像素对调色剂量等效值计算的像素”的每个信号输入值，并且基于修改的信号输入值从加权系数表读出加权系数 。 加权计算装置将信号输入值乘以系数，以便将信号输入值转换成调色剂量当量值。 累积装置计算多值图像的所有像素的调色剂量等效值。 总调色剂量当量值计算部通过累积每次处理图像时分别计算的所有调色剂量等效值来确定总调色剂量当量值。 当总调色剂量当量值达到预定值时，设定用于处理控制的条件。 因此，本发明实现了能够准确地估计调色剂消耗量的图像形成装置。

    Skin wound healing promoters
    10.
    发明授权
    Skin wound healing promoters 失效
    皮肤伤口愈合促进剂

    公开(公告)号：US07071166B2

    公开(公告)日：2006-07-04

    申请号：US10344199

    申请日：2001-08-10

    申请人： Teruo Nishida ,  Katsuhiko Nakata ,  Masatsugu Nakamura

    发明人： Teruo Nishida ,  Katsuhiko Nakata ,  Masatsugu Nakamura

    IPC分类号： A61K38/00

    CPC分类号： A61K38/046 ,  A61K38/30 ,  A61K2300/00

    摘要： The present invention provides healing promoters for skin wounds such as rupture, abrasion, surgical incision, skin ulcer and burn. Coexistence of Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH2 (SEQ ID NO: 1) or Phe-Gly-Leu-Met-NH2 (SEQ ID NO: 2) with insulin-like growth factor-I exhibits a remarkable promotive action on healing the skin wounds. Accordingly, combined administration of at least one of the substance P analogs and pharmaceutically acceptable salts thereof with the insulin-like growth factor exhibits a promotive effect on epidermal extension and a promotive effect on healing the skin wounds.

    摘要翻译： 本发明提供皮肤伤口的愈合促进剂，例如破裂，磨损，手术切口，皮肤溃疡和烧伤。 Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH 2（SEQ ID NO：1）或Phe-Gly-Leu-Met-NH 具有胰岛素样生长因子-1的2型（SEQ ID NO：2）对愈合皮肤伤口有显着的促进作用。 因此，至少一种物质P类似物和其药学上可接受的盐与胰岛素样生长因子的组合给药对表皮延伸表现出促进作用，并且对愈合皮肤伤口具有促进作用。